Abstract
Senescence is defined as an irreversible growth arrest that is characterised by a changed morphology, gene expression pattern and chromatin structure as well as an activated DNA damage response. Senescence has a dual role for tumour development. Firstly, it acts as a tumour suppressor to prevent the proliferation of seriously damaged cells. Important mechanisms ensuring the stop of genomically altered cells to proliferate are the activation of ATM, p53 and the DNA damage response (DDR). In addition it emerges in recent years that oncogene activation acts as a genetic stress and induces senescence as well using similar downstream components: DNA damage activation, changes in gene expression and chromatin structure. Therefore, senescence functions as a powerful tumour suppressor that protects cells expressing activated oncogenes in vivo from becoming neoplastic and malignant. The fact, that oncogene induced senescent cells were mainly found in early, pre-malignant tumour stages suggest that this senescent state has to be overcome during tumourigenesis in order for a tumour to progress to malignancy. At the same time cellular senescence is increasingly recognised as a possible outcome for the treatment of human tumours because it is executed by cells in response to therapeutic treatments, such as drugs and irradiation. While historically apoptosis was considered the only desirable outcome of any anti-neoplastic treatment it emerges recently that senescence could be a potential alternative outcome for tumour therapy in vivo. Animal and tissue culture models have been developed over the last years shedding more light on this novel field of cancer treatment. Whether senescence induction is an advantage or a backdrop for tumour treatment has still to be elucidated since experimental proof in human tumour models is still in an infant stage. This review focuses on the basic mechanisms and recent advances for the induction of senescence as a potential outcome of cancer therapy and discusses the potential for a clinical application.
Keywords: Cancer, senescence, stress, tumour therapy, DNA damage response, oncogene-induced senescence
Current Pharmaceutical Design
Title: Cellular Senescence in the Development and Treatment of Cancer
Volume: 16 Issue: 1
Author(s): Gabriele Saretzki
Affiliation:
Keywords: Cancer, senescence, stress, tumour therapy, DNA damage response, oncogene-induced senescence
Abstract: Senescence is defined as an irreversible growth arrest that is characterised by a changed morphology, gene expression pattern and chromatin structure as well as an activated DNA damage response. Senescence has a dual role for tumour development. Firstly, it acts as a tumour suppressor to prevent the proliferation of seriously damaged cells. Important mechanisms ensuring the stop of genomically altered cells to proliferate are the activation of ATM, p53 and the DNA damage response (DDR). In addition it emerges in recent years that oncogene activation acts as a genetic stress and induces senescence as well using similar downstream components: DNA damage activation, changes in gene expression and chromatin structure. Therefore, senescence functions as a powerful tumour suppressor that protects cells expressing activated oncogenes in vivo from becoming neoplastic and malignant. The fact, that oncogene induced senescent cells were mainly found in early, pre-malignant tumour stages suggest that this senescent state has to be overcome during tumourigenesis in order for a tumour to progress to malignancy. At the same time cellular senescence is increasingly recognised as a possible outcome for the treatment of human tumours because it is executed by cells in response to therapeutic treatments, such as drugs and irradiation. While historically apoptosis was considered the only desirable outcome of any anti-neoplastic treatment it emerges recently that senescence could be a potential alternative outcome for tumour therapy in vivo. Animal and tissue culture models have been developed over the last years shedding more light on this novel field of cancer treatment. Whether senescence induction is an advantage or a backdrop for tumour treatment has still to be elucidated since experimental proof in human tumour models is still in an infant stage. This review focuses on the basic mechanisms and recent advances for the induction of senescence as a potential outcome of cancer therapy and discusses the potential for a clinical application.
Export Options
About this article
Cite this article as:
Saretzki Gabriele, Cellular Senescence in the Development and Treatment of Cancer, Current Pharmaceutical Design 2010; 16 (1) . https://dx.doi.org/10.2174/138161210789941874
DOI https://dx.doi.org/10.2174/138161210789941874 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Viral Reservoirs an Impediment to HAART: New Strategies to Eliminate HIV-1
Current Drug Targets - Infectious Disorders Evolving Strategies for the Treatment of T-Cell Lymphoma: A Systematic Review and Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Calcium Carbonate Microparticles as Carriers of <sup>224</sup>Ra: Impact of Specific Activity in Mice with Intraperitoneal Ovarian Cancer
Current Radiopharmaceuticals Reactive Oxygen and Nitrogen Species in Carcinogenesis: Implications of Oxidative Stress on the Progression and Development of Several Cancer Types
Mini-Reviews in Medicinal Chemistry An update on Anti-inflammatory Compounds: A Review
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Gene Profile Identifies Zinc Transporters Differentially Expressed in Normal Human Organs and Human Pancreatic Cancer
Current Molecular Medicine Recent Patents on Oral Vaccine Design
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) A Genetic Dissection of Antipsychotic Induced Movement Disorders
Current Medicinal Chemistry Gene Expression Signatures of Lymph Node Metastasis in Oral Cancer: Molecular Characteristics and Clinical Significances
Current Cancer Therapy Reviews Methods of Screening-Purification and Antimicrobial Potentialities of Bacteriocin in Health Care
Current Drug Metabolism The Roles of Chromatin Remodeling Proteins in Cancer
Current Protein & Peptide Science Oxytocin and Diabetes Mellitus: A Strong Biochemical Relation. Review
Current Diabetes Reviews Drug-Induced Peripheral Neuropathy: Diagnosis and Management
Current Cancer Drug Targets TWIST1 Gene: First Insights in Felis catus
Current Genomics Targeting the Akt Kinase to Modulate Survival, Invasiveness and Drug Resistance of Cancer Cells
Current Medicinal Chemistry Raman Molecular Imaging of Cells and Tissues: Towards Functional Diagnostic Imaging Without Labeling
Current Pharmaceutical Biotechnology Can Breast Cancer Stem Cells Evade the Immune System?
Current Medicinal Chemistry Apoptosis-Inducing Effects of Amaryllidaceae Alkaloids
Current Medicinal Chemistry The In Vitro and In Vivo Inhibitory Effect of Dehydroaltenusin: A Specific Inhibitor of Mammalian DNA Polymerase α
Current Bioactive Compounds Synthesis, Biological Evaluation, Molecular Docking Study and Acute Oral Toxicity Study of Coupled Imidazole-Pyrimidine Derivatives
Letters in Drug Design & Discovery